{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,22]],"date-time":"2026-09-22T19:11:52Z","timestamp":1790104312882,"version":"4.0.1"},"reference-count":10,"publisher":"Oxford University Press (OUP)","issue":"2","license":[{"start":{"date-parts":[[2025,9,24]],"date-time":"2025-09-24T00:00:00Z","timestamp":1758672000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/pages\/standard-publication-reuse-rights"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2026,1,27]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>Tebentafusp is a novel T-cell receptor-based bispecific protein that targets glycoprotein 100 and CD3. It is the only approved systemic therapy for patients with unresectable or metastatic human leucocyte antigen (HLA)-A*02:01-positive uveal melanoma. Cutaneous toxicities are common, yet there are limited studies in the literature. We conducted a retrospective observational cohort study of patients with HLA-A*02:01-positive unresectable or metastatic uveal melanoma who received tebentafusp therapy from August 2021 to January 2024 at the Royal Marsden NHS Foundation Trust (London, UK), a tertiary referral centre. Cutaneous toxicity occurred in 16\/18 (89%) patients, but reactions were manageable, with no patients permanently discontinuing treatment. To our knowledge, we also report the first case of bullous pemphigoid associated with tebentafusp.<\/jats:p>","DOI":"10.1093\/ced\/llaf426","type":"journal-article","created":{"date-parts":[[2025,9,23]],"date-time":"2025-09-23T11:49:01Z","timestamp":1758628141000},"page":"273-277","source":"Crossref","is-referenced-by-count":1,"title":["Cutaneous toxicities in patients with metastatic uveal melanoma receiving tebentafusp: a retrospective review. The experience of a single large specialist institution"],"prefix":"10.1093","volume":"51","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-2053-8698","authenticated-orcid":false,"given":"Xingyue Maria","family":"Wang","sequence":"first","affiliation":[{"name":"Department of Oncology, Royal Marsden NHS Foundation Trust , London ,","place":["UK"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrew","family":"Furness","sequence":"additional","affiliation":[{"name":"Renal and Skin Unit, Royal Marsden NHS Foundation Trust , London ,","place":["UK"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kara","family":"Heelan","sequence":"additional","affiliation":[{"name":"Dermatology Department, Skin Unit, Royal Marsden NHS Foundation Trust , London ,","place":["UK"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2025,9,24]]},"reference":[{"key":"2026012711324721200_llaf426-B1","author":"US Food and Drug Administration"},{"key":"2026012711324721200_llaf426-B2","doi-asserted-by":"crossref","first-page":"2256","DOI":"10.1056\/NEJMoa2304753","article-title":"Three-year overall survival with tebentafusp in metastatic uveal melanoma","volume":"389","author":"Hassel","year":"2023","journal-title":"N Engl J Med"},{"key":"2026012711324721200_llaf426-B3","doi-asserted-by":"crossref","first-page":"317","DOI":"10.1016\/j.annonc.2023.11.013","article-title":"Overall survival from tebentafusp versus nivolumab plus ipilimumab in first-line metastatic uveal melanoma: a propensity score-weighted analysis","volume":"35","author":"Piulats","year":"2024","journal-title":"Ann Oncol"},{"key":"2026012711324721200_llaf426-B4","doi-asserted-by":"crossref","first-page":"559","DOI":"10.1016\/j.jid.2024.03.048","article-title":"Tebentafusp induces a T cell driven rash in melanocyte-bearing skin as an adverse event consistent with the mechanism of action","volume":"145","author":"Hassel","year":"2025","journal-title":"J Invest Dermatol"},{"key":"2026012711324721200_llaf426-B5","doi-asserted-by":"crossref","first-page":"1196","DOI":"10.1056\/NEJMoa2103485","article-title":"Overall survival benefit with tebentafusp in metastatic uveal melanoma","volume":"385","author":"Nathan","year":"2021","journal-title":"N Engl J Med"},{"issue":"16 Suppl","key":"2026012711324721200_llaf426-B6","doi-asserted-by":"crossref","first-page":"3295","DOI":"10.1158\/1538-7445.AM2020-3295","article-title":"Vitiligo and other clinical melanocyte-related adverse events following tebentafusp (IMCgp100) exposure in patients with uveal melanoma","volume":"80","author":"Orloff","year":"2020","journal-title":"Cancer Res"},{"key":"2026012711324721200_llaf426-B7","doi-asserted-by":"crossref","first-page":"e279","DOI":"10.1111\/ajd.13866","article-title":"A review of the cutaneous toxicities of tebentafusp \u2013 \u200cfeaturing two cases involving superficial bullous reactions","volume":"63","author":"Pham","year":"2022","journal-title":"Australas J Dermatol"},{"key":"2026012711324721200_llaf426-B8","doi-asserted-by":"crossref","first-page":"e207","DOI":"10.1111\/jdv.18625","article-title":"Drug-induced photosensitivity during tebentafusp treatment for metastatic uveal melanoma: a newly described occurrence","volume":"37","author":"Lambertini","year":"2023","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"2026012711324721200_llaf426-B9","author":"US Department of Health and Human Services"},{"key":"2026012711324721200_llaf426-B10","doi-asserted-by":"crossref","first-page":"338","DOI":"10.1111\/ced.14469","article-title":"Cutaneous toxicities in patients with melanoma receiving checkpoint inhibitor therapy: a retrospective review. The experience of a single large specialist institution","volume":"46","author":"Edwards","year":"2021","journal-title":"Clin Exp Dermatol"}],"container-title":["Clinical and Experimental Dermatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/ced\/advance-article-pdf\/doi\/10.1093\/ced\/llaf426\/64358444\/llaf426.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/ced\/article-pdf\/51\/2\/273\/64358444\/llaf426.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/ced\/article-pdf\/51\/2\/273\/64358444\/llaf426.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,1,27]],"date-time":"2026-01-27T16:32:53Z","timestamp":1769531573000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/ced\/article\/51\/2\/273\/8262683"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,9,24]]},"references-count":10,"journal-issue":{"issue":"2","published-online":{"date-parts":[[2025,9,24]]},"published-print":{"date-parts":[[2026,1,27]]}},"URL":"https:\/\/doi.org\/10.1093\/ced\/llaf426","relation":{},"ISSN":["0307-6938","1365-2230"],"issn-type":[{"value":"0307-6938","type":"print"},{"value":"1365-2230","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2026,2]]},"published":{"date-parts":[[2025,9,24]]}}}